Mycophenolate Mofetil for the Treatment of Uveiti Original Reearch Article

Purpoe To evaluate the efficacy and tolerance of mycophenolate mofetil (MMF) for the treatment of noninfectiou uveiti uing the method of analyi advocated by the tandardization of Uveiti Nomenclature (UN) Working Group, and to compare thi with other UN-compliant report of immunouppreion in ocular inflammation. Deign Retropective cae erie. Medhod A predefined data et wa retropectively obtained from the cae note of 100 conecutive uveiti patient treated with MMF at a ingle academic referral center between April 1, 2000 and Augut 1, 2006. Thee data were then analyzed in accordance with UN recommendation. The main outcome meaure were: 1) rate of tapering oral prednione to 10 mg daily, 2) requirement for alternative econd-line immunouppreive therapy, and 3) rate of MMF doe dicontinuation becaue of ide effect. Reult In thi large cohort with noninfectiou peritent, chronic, or recurrent uveiti, there wa an 84.6% probability of achieving a prednione doe of ≤10 mg daily after one year of MMF treatment. Alternative econd-line immunouppreive therapy wa introduced at a rate of 0.18 per patient-year (PY) and MMF wa dicontinued becaue of intolerance at a rate of 0.09/PY, predominantly becaue of gatrointetinal upet. Thi corroborate the finding of the only previou UN-compliant tudy of MMF in ocular inflammation and i comparable to the rate of treatment ucce and intolerance we have recently reported for tacrolimu. Concluion Thi data generate concordant evidence with other UN-compliant tudie upporting the ue of MMF in uveiti.